KRAS and cancer: Although functional genomic screens using primary tumor cells in 3D are technically challenging and have limited throughput, we reasoned that such a screening strategy could have a unique potential to discover novel dependencies relevant for cancers driven by oncogenic KRAS that have not been observed in 2D screens.